Beijing Yicheng Bioelectronics Technology Co., Ltd.

Beijing Yicheng Bioelectronics Technology Co., Ltd. specializes in in vitro diagnostic (IVD) devices designed for self-testing. Their portfolio includes blood glucose test strips, urine microalbumin test strips, blood glucose meters, blood ketone meters, and uric acid test strips. These devices enable individuals to monitor biomarkers like glucose, ketone, and uric acid levels at home or in point-of-care settings, supporting personal health management.

The company is based in China, where it operates under local regulatory frameworks for IVD devices. Since their products are also listed in the EU’s eudamed registry, they must comply with both Chinese and European standards for in vitro diagnostics. This dual compliance ensures their devices meet the necessary requirements for self-testing IVDs in both markets, including classification under applicable regulations.

Devices from Beijing Yicheng Bioelectronics Technology Co., Ltd. are listed in the eudamed registry, which is the EU’s central database for medical devices. This listing ensures traceability and transparency, allowing healthcare professionals, regulators, and patients to verify the device’s existence, classification, and compliance with EU IVD regulations. It also facilitates market surveillance and post-market monitoring.

The company’s devices fall under Class B and Class C in vitro diagnostic (IVD) classifications, which are determined by their intended use and risk level. Class B devices typically involve moderate risk (e.g., blood glucose test strips), while Class C devices pose higher risk (e.g., certain urine or blood-based diagnostics). This classification helps regulators assess compliance requirements, ensuring devices meet safety and performance standards before they reach users.

The company’s devices monitor key biomarkers such as blood glucose, blood ketones, uric acid, and urine microalbumin. Self-testing these biomarkers is relevant because it empowers individuals to monitor chronic conditions like diabetes, metabolic disorders, or kidney health at home. This proactive approach can lead to earlier intervention, better disease management, and improved overall health outcomes.